If you used a product sold as retatrutide and suffered liver damage, Clever Legal can help you investigate whether you may have a claim.
As at 25 August 2026, seven people in Victoria have reportedly been hospitalised with acute liver toxicity after using unapproved products labelled retatrutide. Some of the products have also been sold as Reta, R-10 or R-20.
Samples associated with affected patients are being tested. A contaminated batch is one possible explanation, but that has not been proven. It is also not yet clear whether the cases are connected to one supplier.
What is clear is that the products were not approved for sale in Australia and the injuries reported are serious.
The label is not the product. But uncertainty about what was in the vial does not make the injury less real.
What has happened in Victoria?
Victoria's Chief Health Officer issued an active health alert on 19 June 2026 after six cases of acute liver injury were reported. On 24 August, the ABC reported a seventh Victorian hospitalisation.
The affected patients had used products sold as retatrutide. The Victorian Department of Health says these products may also be labelled Reta, R-10 or R-20 and may be bought online, through friends or on social media.
The latest reports distinguish between two very different things:
- Retatrutide in clinical trials: an experimental medicine that has not been approved for sale in Australia.
- Products being sold as retatrutide: unapproved products whose contents, strength and sterility cannot be assumed from the label.
The Australian product reports do not establish that Eli Lilly's clinical-trial medicine caused the injuries. The concern is about unapproved products being sold under the retatrutide name.
What has been confirmed?
| Confirmed as at 25 August 2026 | Not yet established |
|---|---|
| Seven Victorian hospitalisations involving acute liver toxicity after use of products sold as retatrutide | What each product actually contained |
| Products have been sold under labels including Retatrutide, Reta, R-10 and R-20 | Whether contamination caused each injury |
| Retatrutide is experimental and is not approved for sale in Australia | Whether one batch or supplier connects the cases |
| Samples linked to affected patients are being tested | Whether any seller or provider is legally liable |
The TGA has warned that unapproved peptide products may be poorly labelled and may contain the wrong ingredient, an unknown dose, contaminants or toxins. That warning applies broadly to unapproved peptides. It is not a finding about the precise contents of every product involved in the Victorian cases.
Can you make a retatrutide liver injury claim?
Potentially. A serious injury after using an unapproved product may justify a legal assessment, particularly where a business or individual supplied the product, administered it or recommended it as suitable for use.
Whether there is a viable claim will depend on the individual facts, including:
- who supplied or administered the product;
- what they said about its identity, safety and expected effects;
- whether the product can be linked to the liver injury;
- the seriousness and duration of the injury; and
- the financial and personal loss that followed.
The fact that a product was unapproved does not automatically prove who is responsible. It also does not mean an injured person should assume there is no legal option.
For a plain explanation of the evidence usually needed, read How to establish a medical negligence claim.
What if a beautician, gym or wellness provider supplied it?
The source of the product matters.
The ABC has reported that one affected woman bought a product labelled retatrutide from a beautician. Other patients reportedly used products bought online after recommendations connected with gyms.
If a beautician, gym, wellness provider or Australian seller supplied the product or encouraged its use, the legal assessment may consider what role they played, what representations were made and whether reasonable care was taken.
An overseas website or anonymous social media seller can make a claim harder to pursue. It does not answer whether another person or business in Australia was involved.
Is there a retatrutide class action in Australia?
No retatrutide class action was identified in the public material reviewed as at 25 August 2026.
Seven similar hospitalisations do not automatically create a class action. It is not yet known whether the products came from a common batch or supplier. An affected person's position may need to be assessed as an individual claim while testing and regulatory enquiries continue.
Why Clever Legal may be able to help
Claims involving an unapproved product and an unclear supply chain can be difficult to assess. A traditional firm may decide that the cost of investigating the product, supplier and medical evidence makes the claim commercially unviable.
Clever Legal can consider claims that other firms may not be able to take. We will look at what happened, the seriousness of the injury and whether there is a reasonable next step.
We will not assume that a contaminated batch has been proven or that compensation is automatic. We will give you a clear assessment based on the available evidence.
Speak to Clever Legal
If you used a product sold as retatrutide, Reta, R-10 or R-20 and were diagnosed with liver injury, start a free assessment with Clever Legal.
Tell us who supplied the product, how it was described, when you used it and what happened afterwards. If another law firm has already declined the matter, that does not necessarily mean the injury is not worth investigating.
There is no obligation and no guaranteed outcome. Legal claims are subject to time limits, so seek advice promptly. Read our guide to time limits for medical negligence claims.
Victoria's Department of Health advises people not to use unapproved peptide products. Anyone who develops unusual or concerning symptoms after using one should seek medical attention promptly. In an emergency, call Triple Zero on 000.
This article provides general information and is not legal advice or medical advice.
Sources
- Victorian Department of Health: Toxicity linked to unapproved peptide product labelled Retatrutide, 19 June 2026
- Therapeutic Goods Administration: Warning on the risks of importing unapproved peptide products, 7 May 2026
- ABC News: Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage, 24 August 2026
- ABC News: Warning issued over counterfeit weight-loss drugs labelled as retatrutide, 20 June 2026